The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 12, 2006, Pages 1617-1625

  Norum, Jan ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Adjuvant; Cost effectiveness; Early breast cancer; Trastuzumab

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; EARLY CANCER; EVIDENCE BASED MEDICINE; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH SURVEY; HUMAN; OUTCOMES RESEARCH; OVERALL SURVIVAL; PROTEIN EXPRESSION; RESOURCE ALLOCATION; REVIEW; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 33747055109     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.12.1617     Document Type: Review

References (26)

1. SLAMON DJ, CLARK GM, WANG SG et al.: Human breast cancer; correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
2. SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707-712.
3. KING CR, KRAUS MH, AARONSON SA: Amplification of a novel c-erbB-related gene in a human mammary carcinoma. Science (1985) 229(4717):974-976.
4. SESHADRI R, FIRGAIRA EA, HORSFALL DJ et al.: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J. Clin. Oncol. (1993) 11(10):1936-1942.
5. PRESS MF, PIKE MC, CHAZIN VR et al.: Her-2/neu expression in node negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. (1993) 53(20):4960-4970.
6. PICCART MJ, DI LEO A, HAMILTON A: Her2: a predictive factor ready to use in the daily management of breast cancer patient? Eur. J. Cancer (2000) 36(14):1755-1761.
7. VOGEL CL, COBLEIGH MA, TRIPATHY D et al.: First line Herceptin monotherapy in metastatic breast cancer. Oncology (2001) 61(Suppl. 2):37-42.
8. VOGEL CL, COBLEIGH MA, TRIPATHY D et al.: First-line single-agent Herceptin (trastuzumab) in metastatic breast cancer. A preliminary report. Eur. J. Cancer (2001) 37(Suppl. 1):25-29.
9. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a.monoclonal antibody agianst HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
10. NADLER ES, ECKERT B, NEUMANN PJ: Do oncologists believe new cancer drugs offer good value? Proc. Am. Soc. Clin. Oncol. (2005) 23:a6011.
11. DRUMMOND MF, SCULPHER MJ, TORRANCE GW, O'BRIAN BJ, STODDART GL: In: Methods for the Economic Evaluation of Health Care Programmes (third edn). Oxford University Press, Oxford, UK (2005).
12. ROMOND RH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl. J. Med. (2005) 353(16): 1673-1684.
13. PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
14. JOENSUU H, KELLOKUMPU-LEHTINEN PL, BONO P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. (2006) 354(8):809-820.
15. SLAMON D, EIERMANN W, ROBERT N et al.: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. BCIRG 006 study. In: San Antonio Breast Cancer Symposium, December 8-11 (2005), San Antonio, TX, USA. Abstract 1069. (Available at www.abstracts2view.com/sabcs05).
16. NEYT M, ALBRECHT J, COCQUYT C: An economic evaluation of Herceptin in adjuvant setting. The breast cancer international research group 006 trial. Ann. Oncol. (2006) 17(3):381-390.
17. HILLNER BE: Clinical and cost-effectiveness implications of the adjuvant traatuzumab in HER2+ breast cancer trials. In: San Antonio Breast Cancer Symposium, December 8-11 (2005), San Antonio, TX, USA. Abstract 5040. (Available at www.abstracts2view.com/sabcs05).
18. RAGAZ J, SPINELLI JJ: Cost-benefit estimates of adjuvant (Adj) trastuzumab (herceptin, H) for early breast cancer (BrCa). In: San Antonio Breast Cancer Symposium, December 8-11 (2005), San Antonio, TX, USA. Abstract 2029. (Available at www.abstracts2view.com/sabcs05).
19. DANISH NATIONAL BOARD OF HEALTH: Trastuzumab (Herceptin) in adjuvant treatment of early breast cancer following surgery. Preliminary report. Medicinsk Teknologivurdering av krœftlegemidler (2005) 1(3):1-21 (Available in English at http://www.sundhedsstyrelsen.dk/upload/planlaegning_og_behandling/ cemtv/mtv_af_nye_kr%C3%A6ftl%C3%A6gemidler/herceptin_en/ herceptin_en.pdf).
20. DE LAURENTIIS M, CANCELLO G, ZINNO L et al.: Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann. Oncol. (2005) 16(Suppl. 4):iv7-iv13.
21. EVANS WK, WILL PB, BERTHELOT JM et al.: Breast cancer: better care for less cost. Int. J. Technol. Assess. Health Care (2000) 16(4):1168-1178.
22. TAN-CHIU E, YOTHERS G, ROMOND E et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therpy in node-positive human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B31. J. Clin. Oncol. (2005) 23(31):7811-7819.
23. CROWN J, EIERMANN W, ROBERT N et al.: Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/ trastuzumab (AC-TH) produce superior disease-free-survival (DFS) compared to AC-T in patients (pts) with HER-2 positive early breast cancer (EBC), with increased cardiotoxicity confined to AC-TH: BCIRG 006 study. Eur. J. Cancer Suppl. (2006) 4(2):108. Abstract 208.
24. BASELGA J: Herceptin adjuvant trials - 2006 update. Eur. J. Cancer Suppl. (2006) 4(2):108. Abstract 436.
25. HORTOBAGYI GN: Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. (2005) 353(16):1734-1736.
26. NORUM J, RISBERG T, OLSEN JA: A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann. Oncol. (2005) 16(6):909-914.